Emerging Diagnostic and Prognostic Biomarkers of Triple Negative Breast Cancer

DOI: 10.26717/BJSTR.2017.01.000245

Received: July 19, 2017;   Published: August 01, 2017

To view the Full Article   Peer-reviewed Article PDF

Abstract

Triple negative breast cancer is one the most frequently diagnosed and major causes of cancer deaths among young women. Generally, mammography is used to detect breast cancer at an early stage. Magnetic resonance imaging (MRI) in addition to mammography is recommended for annual screening. Breast ultrasound is sometimes used to evaluate abnormal findings. However, these methods increase the likelihood of false-positive results. TNBC cells express or release some molecules into the blood stream and other body fluids at quite low level and their levels increase with cancer progression. The present review is aimed to update the currently available conventional and emerging biomarkers, and presenting the most effective biomarkers for early diagnosis and prognosis of TNBC.

Abstract| Introduction| Conclusion| Acknowledgement| References|